FDA Approves Merck's First Oral Cholesterol Pill

Pro-establishment narrative

The FDA approval of Lipfendra is a landmark moment in cardiology — a once-daily pill matching injectable PCSK9 inhibitors in LDL reduction while also lowering ApoB and Lp(a). Millions who refused injections now have a real option. At $315 a month, it's more accessible, and for the 9.8 million high-risk Americans still off target, this changes everything.